STOCK TITAN

Mary Lynne Hedley Elected to Lilly Board of Directors

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
management
Rhea-AI Summary

Eli Lilly and Company (NYSE: LLY) has elected Dr. Mary Lynne Hedley to its Board of Directors, effective May 15, 2022. Dr. Hedley, an expert in immunology and oncology, brings extensive experience from her roles at the Broad Institute and TESARO, a biotech firm she co-founded. She will serve on the Science & Technology Committee and the Ethics and Compliance Committee. CEO David A. Ricks expressed optimism about her addition, highlighting her leadership and technological insights as vital to Lilly's ongoing innovation and growth in the pharmaceutical industry.

Positive
  • Dr. Hedley's expertise in oncology and pharmaceutical industries may enhance Lilly's strategic direction.
  • Her experience with biotechnology companies could foster innovation and leadership on the board.
Negative
  • None.

INDIANAPOLIS, May 6, 2022 /PRNewswire/ -- The Board of Directors of Eli Lilly and Company (NYSE:LLY) has elected Mary Lynne Hedley, Ph.D., as a new member, effective May 15, 2022. As a member of Lilly's board, she will serve on both the Science & Technology Committee and the Ethics and Compliance Committee. 

Dr. Hedley is an immunologist and cancer cell biologist with considerable pharmaceutical industry experience, particularly within oncology. Since 2021, Dr. Hedley has served as a Senior Scientific Fellow at the Broad Institute of MIT and Harvard. Prior to that, she served as Director, President, and Chief Operating Officer at TESARO, Inc., a biotechnology company she co-founded in 2010, focused on the development and global commercialization of oncology therapeutics. GlaxoSmithKline plc acquired TESARO in 2019. Prior to founding TESARO, Dr. Hedley was Executive Vice President and Chief Science Officer of Abraxis Bioscience, Inc., where she was responsible for research and development, operations, medical affairs, and business development.

"I am delighted to welcome Dr. Mary Lynne Hedley to the Lilly Board of Directors," said David A. Ricks, chairman and chief executive officer. "Mary Lynne has valuable expertise in oncology and the pharmaceutical industry more broadly. Her experience in founding, scaling, and leading biotechnology companies will add tremendous technological and leadership insight to our board."

Dr. Hedley received her Bachelor of Science degree in Microbiology from Purdue University and her Ph.D. in Molecular and Cellular Immunology from UT Southwestern Medical Center. Dr. Hedley completed her postdoctoral training at Harvard University in the areas of immunology and gene regulation.

About Lilly  
Lilly unites caring with discovery to create medicines that make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer's disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/newsroom. C-LLY

Refer to:   

Jordan Bishop; jordan.bishop@lilly.com; 317-473-5712 (Media)      


Kevin Hern; hern_kevin_r@lilly.com; 317-277-1838 (Investors)

 

Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mary-lynne-hedley-elected-to-lilly-board-of-directors-301541193.html

SOURCE ELI LILLY AND COMPANY

FAQ

Who is the new board member elected by Eli Lilly on May 6, 2022?

Dr. Mary Lynne Hedley was elected to the Board of Directors of Eli Lilly.

What experience does Dr. Mary Lynne Hedley bring to Eli Lilly?

Dr. Hedley has extensive experience in immunology and oncology, previously serving at TESARO and the Broad Institute.

What committees will Dr. Hedley serve on at Eli Lilly?

Dr. Hedley will serve on the Science & Technology Committee and the Ethics and Compliance Committee.

When will Dr. Hedley officially join the Eli Lilly Board of Directors?

Dr. Hedley will officially join the Board of Directors on May 15, 2022.

What impact might Dr. Hedley's election have on Eli Lilly's future?

Her expertise could provide valuable insights and strengthen Lilly's focus on oncology and innovative therapies.

Eli Lilly & Co.

NYSE:LLY

LLY Rankings

LLY Latest News

LLY Stock Data

685.15B
950.41M
0.15%
83.32%
0.7%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
INDIANAPOLIS